Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16321007 | 0.87 | NPC1 (0.50) | MMP9MMP14MMEFOLH1NPC1 | |
| SCHEMBL16321006 | 0.87 | NPC1 (0.50) | MMP9MMP14MMEFOLH1NPC1 | |
| SCHEMBL3848650 | 0.86 | ALDH1A1 (0.49) | MMP9NPC1RAB9AMTNR1AMTNR1B | |
| SCHEMBL12019756 | 0.86 | HPGD (0.61) | MMP9MMP14NPC1RAB9APPARA | |
| SCHEMBL13753851 | 0.86 | HPGD (0.61) | MMP9MMP14NPC1RAB9APPARA | |
| SCHEMBL16633697 | 0.84 | MMP9 (0.49) | MMP9MMP14MMEFOLH1NPC1 | |
| SCHEMBL20603266 | 0.84 | MMP9 (0.49) | MMP9MMP14MMEFOLH1NPC1 | |
| SCHEMBL16633700 | 0.84 | MMP9 (0.49) | MMP9MMP14MMEFOLH1NPC1 | |
| SCHEMBL16758733 | 0.83 | FOLH1 (0.51) | MMP9MMP14MMEFOLH1PPARA | |
| SCHEMBL25415515 | 0.83 | TACR1 (0.49) | MMP9MMP14MMEFOLH1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-03 | — | — | US | disclosed |
| EP-3700907-B1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AG (DE) | 2022-03-09 | — | — | EP | disclosed |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319324-B2 | Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX5 | MMP9 3662/4885MMP14 4689/4885MME 3743/4885 |
| US-20210317128-A1 | NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX1, P2RX5 | MMP9 3913/4885MMP14 4780/4885MME 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.